Pulmonx Corporation (LUNG)

Nasdaq: LUNG · Surgical & Medical Instruments & Apparatus · Redwood City, CA · filing with the SEC since 2003

Full chart Alerts Compare

Grade5.6

◀ Past 7.0● Present 5.0▶ Future 4.9

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$90.5M+8.0%

Net income-$54.0M+4.2%

Earnings per share$-1.33+7.6%

Operating cash flow-$32.4M-2.7%

Cash$70.0M-1.6%

Debt$37.1M-0.2%

Shareholders’ equity$54.1M-36.9%

Shares, diluted40.7M+4.0%

Return on equity-99.8%

The recordfrom its filings

Filings in 202641

Newest filingNov 5 · SCHEDULE 13G/A

Annual reportMar 10, 2026

Quarterly reportNov 3, 2026

Next report due10-K by Mar 31

Insider sales, 12 months$500,000

Insider buys, 12 months$0.00

Patents granted90

Filer categoryNon-accelerated filer<br>Smaller reporting company

Trailing twelve months to Sep 2026Revenue $88.8MNet income -$42.6MCash from operations -$25.6Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

1819202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 5, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Nov 3, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Oct 27, 2026 · SEC EDGAR · Form 8-K

Results released

Open the filing on sec.gov

Sep 3, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Sep 3, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Sep 3, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Sep 3, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Aug 13, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

Aug 4, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Jul 29, 2026 · SEC EDGAR · Form SCHEDULE 13G/A

Large holder update, amended

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

Pulmonx Corporation is classed by the SEC under Surgical & Medical Instruments & Apparatus (industry code 3841), based in Redwood City, CA.

Newest on the record

Large holder update, amended on Nov 5. Before it, quarterly report on Nov 3.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 31, 2027.

About LUNG

Pulmonx Corporation is classed by the SEC under Surgical & Medical Instruments & Apparatus (industry code 3841), based in Redwood City, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $90 million and a loss of $54 million (its filed statements).

IndustrySurgical & Medical Instruments & Apparatus

HeadquartersRedwood City, CA

Business modelProduct business

ExchangeNasdaq

Filing since2003

Fiscal year endsDec 31

SEC number (CIK)1127537

Peers on fileCARL, DCTH, UTMD, GUTS

Who runs it

Financial performance

In fiscal 2025 Pulmonx’s revenue was $90.50 million, up 8.0% from $83.79 million the year before. It made a net loss of $54.00 million.

Annual report, filed Mar 10, 2026.

Financial statements

The grade

Pulmonx grades 5.6 of 10 against its own industry, the 121 companies in Surgical & Medical Instruments & Apparatus. Eight of the nine metrics are read as filed and one is an SI estimate, each with its reasoning.

◀ Past7.0

● Present5.0

▶ Future4.9

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton LUNG · research, not advice